ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

In an interview with Targeted Oncology at the ILCA conference, Rimola, radiologist, Radiology Department, Barcelona Clinic Liver Cancer Group, University of Barcelona, explained how assessment criteria may change patterns of progression and ultimately change outcomes in patients with advanced HCC treated with nivolumab.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.